| Today’s Big NewsFeb 7, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. Register now.
|
|
| By Nick Paul Taylor Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be Sotyktu successor. |
|
|
|
By Fraiser Kansteiner Bain Capital is laying out 510 billion Japanese yen ($3.3 billion) to acquire Mitsubishi Tanabe Pharma in a carve-out transaction from its parent Mitsubishi Chemical Group. The deal, which is expected to close in 2025’s third quarter, will set up Tanabe Pharma as an independent company, Bain said. |
By Angus Liu Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward autoimmune diseases in 2024. Now, CEO Nadim Ahmed wants to reset expectations, hoping that speed and a “thriller or killer” approach will be his friends as the company navigates both competitive fields. |
By James Waldron Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity biotech Aardvark Therapeutics unveiled plans for a nine-figure IPO of its own. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now.
|
|
By James Waldron Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger. |
By Nick Paul Taylor Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to reductions in treated bleeds in children with the hereditary bleeding disorder. |
By Gabrielle Masson Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide seller Novo Nordisk—with its blockbuster molecule tirzepatide. Now, with a pipeline chock-full of numerous incretin therapies, the Big Pharma's new strategy will be to test some of those drugs across neurology and immunology indications. |
By Darren Incorvaia,Zoey Becker Veteran scientist Hideo Makimura, M.D., Ph.D., is going fully preclinical by joining gene therapy biotech Affinia Therapeutics as chief medical officer. Makimura most recently served in leadership roles at J&J. |
By Darren Incorvaia After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is climbing closer to its goal of accelerated approval by unveiling data showing the drug met its primary safety endpoints and reduced key biomarkers of the disease. |
By Darren Incorvaia After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to an experimental, personalized cancer vaccine, researchers reported Feb. 5. |
By Andrea Park,Eric Sagonowsky This week on "The Top Line," we dig into the 10 biggest potential drug launches of 2025, predicted to rake in a combined $29 billion in annual sales by the end of the decade. |
By Angus Liu Johnson & Johnson's proposed $14.6 billion purchase of Intra-Cellular Therapies took just one month from the time the buyer revealed its intention to the signing of the deal. The process involved a key intervention from J&J’s CEO Joaquin Duato, a securities filing shows. |
By Fraiser Kansteiner In a lawsuit that received little attention toward the end of last year, Regeneron has taken Sanofi to court over claims that its marketing and development partner violated the terms of a long-standing Dupixent collaboration. Regeneron disclosed the lawsuit in an annual filing this week. |
By Angus Liu Merck & Co. and AstraZeneca suffered notable losses in China during the fourth quarter. Astellas shuffled its C-suite and revealed a slowdown for its newly launched eye disease med Izervay. Plus more. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we dig into the 10 biggest potential drug launches of 2025, predicted to rake in a combined $29 billion in annual sales by the end of the decade. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now.
|
|
| Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
